Chapter 38: Drugs Acting on the Renin-Angiotensin-Aldosterone System

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine a survival mechanism so ancient and powerful that it kept our ancestors alive through severe hemorrhages, crushing traumas, and like extreme droughts.

Right, the body's ultimate defense system.

Exactly.

But now, imagine that exact same life -saving mechanism being weaponized against you by a modern high sodium diet and a sedentary lifestyle.

Yeah, it really is the ultimate physiological paradox.

It really is.

Welcome to the Deep Dive.

Today, we're teaming up with the Last Minute Lecture crew for a specialized session tailored specifically for you, our advanced practice nursing and physician assistant students.

We're zeroing in on chapter 38 of Len's pharmacotherapeutics, which is all about the renin angiotensin aldosterone system or the RAS.

And you know, mastering the drugs that act on the RAS,

it isn't just an academic exercise to pass your pharmacology boards.

This system is the absolute core of cardiovascular prescribing.

Oh, 100%.

It's huge.

Yeah.

I mean, when you're sitting in the clinic with a patient who has hypertension or you're managing someone who just survived a myocardial infarction, your understanding of this cascade is what dictates safe patient -centered care.

So to build that clinical intuition, we have to, you know, start with the plumbing before we try to fix the pipes.

Let's unpack the pathophysiology first.

Sounds good.

Where do you want to start?

Well, we hear a lot about the angiotensin family, right?

Like angiotensin, the third, third and third.

Right.

But they definitely don't all carry the same weight, do they?

No, not at all.

Angiotensin, think, is essentially just a precursor waiting to be activated.

It has very, very weak biologic activity.

Okay.

So it's just kind of hanging out.

Exactly.

And then angiopensin, the third, which is a byproduct formed when angiotensin second degrades, that one has moderate activity.

But the absolute star of this show, the compound driving this entire cardiovascular response is angiotensin, the second.

It is incredibly potent.

And here's where it gets really interesting.

It's that double -edged sword we were just talking about, right?

Like in a short -term crisis, say you're in a car accident and losing blood angiotensin, the second is your best friend.

Oh, absolutely.

It's the ultimate pressure preserver.

When your blood volume drops precipitously, angiotensin, the second acts directly on the vascular smooth muscle to cause powerful immediate vasoconstriction.

And that's primarily in the arterioles, right?

Yes, primarily the arterioles.

But it doesn't stop there.

It also stimulates the sympathetic nervous system to release norepinephrine, and it prompts the adrenal medulla to release epinephrine.

Wow.

So you get this massive coordinated squeeze to keep your blood pressure up so your vital organs don't just fail.

Exactly.

But the flip side is the long -term reality for our modern patients.

If angiotensin, the second, stays chronically elevated,

structurally, it is incredibly destructive to the cardiovascular system.

Because it fundamentally changes the architecture of the heart and the blood vessels over time.

In the heart, it drives pathologic hypertrophy and cardiac remodeling.

It literally increases the migration, proliferation, and thickening of vascular smooth muscle cells and cardiac myocytes.

So in a patient with hypertension or heart failure, this chronic remodeling leads to stiffness, fibrosis, and ultimately a heart that just cannot pump effectively.

Yeah.

It's a vicious cycle.

And angiotensin, the second, doesn't work alone.

It has a partner in crime pushing this pathology further, which is aldosterone.

Ah, yes.

Aldosterone enters the chat.

It sure does.

Angiotensin, the second, acts on the adrenal cortex to stimulate the synthesis and release of aldosterone.

And the adrenals are so exquisitely sensitive to it that even a tiny amount of angiotensin, second levels, too low to even cause vasoconstriction, will still trigger aldosterone release.

So aldosterone travels down to the distal tubules of the kidneys and goes to work.

And its primary directive is to retain sodium and water and to kick out potassium and hydrogen.

Exactly.

That sodium and water retention increases blood volume, driving blood pressure even higher.

And just like angiotensin, the second, aldosterone promotes cardiac fibrosis and can actually predispose the heart tissue to dangerous dysrhythmias.

Which is why we need to visualize the cascade of how these hormones are formed.

It all starts with renin, which is an enzyme produced by the juxtaglomerular cells in the kidney.

And when your blood pressure, your blood volume, or your plasma sodium content drops,

those cells release renin into the bloodstream.

Let's use an analogy here to make this stick for everyone listening.

Think of the RAAS like the automated thermostat in your house.

Oh, I like that.

Yeah.

So when the temperature, or in this case, the blood pressure drops too low, the sensor triggers the furnace, which is renin, to kick on.

The finest pumps out heat, raising the pressure.

And eventually, a negative feedback loop tells the system, you know, we're warm enough, and it shuts the renin release off.

That is a perfect way to conceptualize it.

So renin is in the blood, and its only job is to catalyze the formation of angiotensin I from a protein called angiotensinogen.

And this is the rate -limiting step of the entire system, right?

It is.

Once you have angiotensin VI, the next critical player swoops in, which is angiotensin -converting enzyme, or ACE.

And ACE is everywhere, right?

Especially on the luminal surface of all your blood vessels, and highly concentrated in the lungs.

It is ubiquitous.

ACE converts that inactive angiotensin A into the highly active angiotensin II almost instantaneously.

So the moment you understand that cascade, the therapeutic interventions become obvious.

Because if this system is causing pathological remodeling and high blood pressure, we have to block it.

Exactly.

But before we start throwing molecular wrenches into this cascade, we have to look at who we're treating.

Clinical guidelines highlight some massive differences in how this system responds in specific populations.

Right.

I mean, for instance, in kids over six, we can use certain RALS blockers for hypertension pretty safely.

But for pregnant people, it is a hard stop.

An absolute hard stop.

Drugs that block the RALS must be completely avoided in pregnancy, especially in the second and third trimesters.

Because the clinical data and animal studies show severe fetal harm, right?

Yes, including fetal skull hypoplasia, anuria,

renal failure, and even fetal death.

It carries a black box warning for a reason.

If a patient becomes pregnant while on these medications, they need to stop them immediately.

That's a huge safety priority.

But then on the flip side of the AIDS spectrum, for older adults, the clinical trials actually show incredible benefits.

They really do.

The Scope in Life trials demonstrated a 25 % decrease in stroke risk for older patients using an ARB like Losartan compared to a beta blocker.

And didn't another trial even show a 20 % decreased risk for new onset diabetes?

Yes, exactly.

So we know the stakes and we know the targets.

The most logical place to intervene is to target the enzyme that actually makes the destructive compound.

Which brings us to our frontline defense, the ACE inhibitors, the classic PRL drugs, you know, glycinopril, captopril, and alipril.

Right.

When we prescribe these, we are fundamentally altering the chemical environment in the blood vessels.

ACE inhibitors do two distinct things.

First, they reduce levels of angiotensin the second, which causes vasodilation, reduces blood volume, and helps reverse that pathological cardiac remodeling we talked about.

Okay.

But the second mechanism is just as crucial and it's the one that causes the most clinical headaches.

Oh, definitely.

ACE inhibitors also increased levels of bradykinin.

And why is that?

Because angiotensin converting enzyme is structurally the exact same enzyme as kinase 2.

And kinase the second is the enzyme responsible for breaking down bradykinin.

Oh, wow.

That is fascinating.

So if you inhibit ACE to stop angiotensin the second, you are simultaneously inhibiting kinase 2.

The bradykinin doesn't get broken down, so it just accumulates.

Precisely.

That extra bradykinin causes additional vasodilation, which is, you know, great for lowering blood pressure.

But that buildup, particularly in the lungs, is what causes some notorious adverse effects.

We will definitely get into those side effects.

But as a student, the pharmacokinetics of ACE inhibitors are a massive trap on exams.

You really have to know the exceptions to the rules.

Yeah.

The general rules are that they're taken orally.

They have long half -lives, so they're once or twice a day.

They're pro -drugs that the liver has to convert to an active form, and they are excreted by the kidneys.

But the clinical reality is far more nuanced, and those nuances dictate your prescribing.

Let's look at the exceptions.

First, Anilobrachylet is the only ACE inhibitor administered intravenously.

Which is absolutely vital for hypertensive emergencies.

Right.

Second, Captopril has a very short half -life.

You have to dose it two or three times a day, and it must be taken on an empty stomach.

Think about how that impacts a patient's daily adherence compared to taking one pill in the morning.

It's a huge barrier.

Yeah.

And then there's lisinopril, which is active right out of the bottle.

It is not a pro -drug.

And that is a game -changer if you have a patient with severe liver impairment who can't efficiently convert a pro -drug into its active form.

Exactly.

And the final exception is critical for renal safety.

Because these drugs are excreted by the kidneys, almost all of them require a dosage reduction in patients with renal impairment to prevent toxic accumulation.

Except for fulsnumarple.

Fulsnopril is the lone exception and does not require that renal dosage adjustment.

Okay, so we're prescribing these for essential hypertension, heart failure, acute MI.

But wait, I want to push back on one of their major indications, slowing diabetic nephropathy.

Okay, let's hear it.

If these drugs actively lower blood pressure, which drops the pressure inside the kidney, how does that protect a diabetic patient's kidney?

Doesn't the kidney require high pressure to actually filter the blood?

It is one of the most common points of confusion.

But the underlying pathophysiology is brilliant.

Think about the structure of the glomerulus.

You have blood flowing in through the afferent arteriole and flowing out through the efferent arteriole.

Okay, I'm picturing it.

Normally, angiotensin II preferentially constricts that efferent arteriole, the exit pipe.

Okay, so it's exactly like putting your thumb over the end of a garden hose.

The water is still coming in, but you've narrowed the exit.

So the pressure inside the hose or the glomerular capillary bed just skyrockets.

That's it, exactly.

And in a diabetic patient, that massive, sustained, intraglomerular back pressure is what mechanically damages the delicate kidney tissue over time.

Oh, I see.

So when you give an ACE inhibitor, you lower the angiotensin II levels,

the efferent arteriole dilates, you're taking your thumb off the hose, the pressure inside the glomerulus drops significantly, which drastically slows the rate of structural injury.

That makes perfect sense.

It's not just lowering systemic blood pressure, it's fixing the localized plumbing issue inside the kidney itself.

But of course, taking our thumb off the hose comes with risks.

We have to talk about the adverse effects, starting with first dose hypotension.

Yeah, the widespread vasodilation can cause a precipitous drop in blood pressure after that very first pill.

It is a major syncope risk.

So your patient education needs to be highly specific, right?

Absolutely.

You instruct them to take that first low dose right before bed, so they're already lying down and have them monitor their blood pressure at home.

Makes sense.

Then we have to deal with the famous ACE cough.

Ah, yes, the persistent, dry, nonproductive tickly cough.

This affects roughly 10 % of patients, and it is the single most common reason patients refuse to keep taking the drug.

And going back to our mechanism, this is caused by that accumulation of bradykine in the lungs, right?

Yes.

And it tends to be more common in older adults, females, and patients of Asian ancestry.

We also have to watch for hyperkalemia.

Because we are suppressing aldosterone, which normally kicks potassium out of the body, the patient is now holding onto it.

Potassium levels can creep up to dangerous arrhythmia -inducing levels.

Yeah, you have to actively warn your patients to avoid potassium supplements, and crucially, those salt substitutes at the grocery store.

Because they're essentially pure potassium chloride.

Exactly.

And we cannot discuss ACE inhibitors without highlighting the most severe safety alert, angioedema.

Oh, yeah, that's a big one.

It occurs in about 1 % of patients in presence, as giant wheels and massive edema of the tongue, glottis, lips, and pharynx.

It can compromise the airway in minutes.

So if a patient develops angioedema, you treat it emergently with subcutaneous epinephrine, and they must never, ever be prescribed an ACE inhibitor again.

Never.

And we already covered the black box warning regarding fetal injury, but there is one very specific absolute contraindication you will absolutely see on your boards and in the clinic, and that's bilateral renal artery stenosis.

This goes right back to the thumb on the hose analogy, doesn't it?

It sure does.

If a patient has severe narrowing in both renal arteries, blood flow into the kidney is already terribly compromised.

In this specific scenario, the kidneys are relying entirely on that high angiotensin, the second back pressure, just to maintain any glomerular filtration at all.

Right.

So if you give an ACE inhibitor and take the thumb off the hose, their filtration pressure drops to zero, their urine production stops, and they go into acute renal failure.

Precisely.

It's a disaster.

So what does this all mean for our prescribing flow?

Say you have a patient, let's call them Mr.

Smith, in your clinic.

He had a heart attack, you put him on Lysinople to prevent cardiac remodeling, but he comes back a week later and he hasn't slept in three days because of that dry, hacking, Brady Kinnon cough.

You need a Plan B.

Which leads us directly to the angiotensin, the second receptor blockers, or ARBs, the sartan drugs, valsartan, lussartan, herbisartan.

They solve the Brady Kinnon problem by changing where we intervene in the cascade.

Right.

Instead of inhibiting the ACE enzyme that actually makes angiotensin, the second,

ARBs let the body make all the angiotensin, the second it wants, but they block the actions of it at the actual receptor sites in the blood vessels, the heart, and the adrenals.

And here is the crucial distinction.

Because they do not inhibit the ACE enzyme, which remember is kinase 2, they do not interfere with the breakdown of Brady Kinnon.

So no Brady Kinnon accumulation means no cough.

Exactly.

No cough.

Okay, let's unpack this.

If ARBs block the same physiological effects without the Annorin cough, why aren't they our first line choice for everyone?

Well, it comes down to the weight of clinical evidence.

While the physiologic end results look similar on paper,

ACE inhibitors have decades of robust, extensive gold standard evidence proving they significantly decrease cardiovascular morbidity and mortality.

And the data for ARBs.

The clinical trial data for ARBs, while good, is simply less convincing across the board compared to ACEs.

So the standard of care remains, ACE inhibitors are the preferred first line champions.

ARBs are the highly effective understudies reserved mainly for patients like Mr.

Smith, who absolutely cannot tolerate the ACE inhibitor cough.

Exactly.

And their therapeutic uses mirror the ACE inhibitors, hypertension, heart failure, specifically valsartan and canisartan, diabetic nephropathy, mostly herbisartan and losartan, and post -MI protection.

They share a lot of the same safety profiles too, right?

Like a lower risk of hyperkalemia than ACEs, but they carry that identical black box warning for fetal harm.

Yep.

And that same absolute contraindication for bilateral renal artery stenosis.

But what about the angioedema risk?

If a patient had life -threatening airway swelling on an ACE, is it safe to just switch them to an ARB?

Now that is a critical clinical judgment call.

The data shows an 8 % cross -reactivity rate.

Wait, 8 %?

Yeah.

Meaning roughly 8 % of patients who develop an angioedema with an ACE inhibitor will also develop it with an ARB.

So it is not a zero -risk switch.

You have to look at the patient in front of you and weigh that potential 8 % risk against the known proven benefits of an ARB for their specific condition,

like heart failure.

That makes a lot of sense.

All right.

Let's keep moving up the chain.

We've blocked the enzyme and we've blocked the receptor, but why not just shut down the entire factory before it even gets started?

What do you mean?

Well, if renin is the catalyst for the whole cascade, why don't we just use direct renin inhibitors or DRIs?

It is a brilliant theoretical question, and it's the exact logic behind L -Iskrin, which is the only approved DRI on the market.

L -Iskrin binds tightly to renin itself, preventing it from ever converting angiotensinogen into angiotensin I.

So you suppress the entire downstream cascade right at the source.

Right.

But, you know, theory doesn't always survive contact with human biology.

The pharmacokinetics of L -Iskrin are honestly pretty rough.

Really?

How so?

It has extremely low bioavailability.

Only about 2 .5 % of an oral dose actually makes it into the systemic circulation.

And if the patient takes it with a high -fat meal,

absorption plummets even further, down to less than 1%.

Oh, wow.

That is terrible.

But beyond the absorption issues, we have to look at the clinical outcomes.

You asked why we don't just use this to shut down the factory.

The text details a major clinical study called the Altitude Trial.

Ah, yes.

The L -Iskrin trial in type 2 diabetes using cardiorenal disease endpoints.

And didn't that trial get shut down early?

What went wrong?

It was halted prematurely because the results were alarming.

The patients taking L -Iskrin alongside standard therapy actually experienced higher incidences of non -fatal stroke, renal dysfunction, hyperkalemia, and severe hypotension compared to the placebo group.

Wow.

So blocking the system perfectly at the source actually resulted in worse real -world outcomes for those diabetic patients.

It just goes to show that human physiology has complex feedback loops we don't fully understand yet.

It is a sobering reminder for all prescribers.

Just because a drug's mechanism of action makes perfect logical sense on a whiteboard doesn't mean it translates to increased patient survival.

Exactly.

The clear takeaway for students is to stick to older proven evidence -based antihypertensives first until we have more definitive long -term data on DRIs.

Okay, we are in the home stretch.

We've covered the top and the middle of the cascade.

Now we need to look at the very end of the line.

We are talking about the aldosterone antagonists designed to block that hormone responsible for massive sodium retention and cardiac fibrosis.

Right.

These are your potassium -sparing drugs.

By blocking the aldosterone receptors in the distal tubules of the kidney,

these medications promote sodium and water excretion, which lowers blood volume and pressure.

But more importantly for heart failure patients, they block the pathological fibrotic effects of aldosterone on the heart muscle itself.

Exactly.

Let's compare the two heavy hitters in this class, spironolactone and Epidon, because the differences between them are purely structural, but they cause wildly different patient experiences.

Let's start with the older one, spironolactone.

Well, spironolactone is a non -selective aldosterone antagonist.

It does a fantastic job blocking aldosterone, giving you all the cardiovascular benefits.

But structurally, spironolactone looks an awful lot like other steroid hormones in the body.

Right.

Because it's non -selective, it spills over and binds to receptors for glucocorticoids, progesterone, and androgens.

And that spillover creates a cascade of unintended endocrine side effects.

By binding to those other steroid receptors, spironolactone can cause gynecomastia or breast tissue enlargement in menstrual irregularities in women,

impotence, hirsutism, and even a deepening of the voice.

Which, as you can imagine, leads to massive adherence issues.

Patients do not want to take a heart medication that profoundly alters their endocrine system.

Understandably.

So pharmacology advanced, and we got eponone.

Yes.

Eponone is the first in class selective aldosterone receptor blocker.

It binds tightly to the aldosterone receptors, but leaves the antigen and progesterone receptors alone.

So you get the blood pressure and heart failure benefits.

It's actually been shown to prolong life in heart failure patients without the gynecomastia or menstrual issues.

Exactly.

But the selectivity doesn't mean it's perfectly safe.

The massive safety priority with both of these drugs is severe hypercolonia.

Because they block aldosterone so effectively, the body holds on to potassium with an iron grip.

Right.

So eponone is strictly contraindicated if a patient's baseline serum potassium is already above 5 .5.

Yes.

And you also cannot safely combine it with other potassium -bearing diuretics or potassium supplements.

And there is a dangerous drug interaction with eponone that students must memorize.

Eponone is metabolized in the liver by the CYP3A4 enzyme.

So if you prescribe a strong CYP3A4 inhibitor, like the antifungal ketoconazole or certain antibiotics, the liver stops metabolizing the effleuronone.

The drug levels can increase fivefold in the bloodstream, leading to life -threatening toxicity and hypercolemia.

It requires extreme vigilance.

You are balancing incredible cardiac protection against the constant threat of fatal arrhythmias from high potassium.

Let's bring this all together.

The clinical framework we've built today gives you a strategic menu for prescribing.

The RAS cascade is an ancient survival tool that turns pathological and chronic disease states.

Exactly.

As a clinician, you get to choose exactly where to break the chain.

You can block the converting enzyme with an ACE inhibitor.

You can block the vascular receptors with an ARB.

You can try to inhibit the initial catalyst with a DRI.

Or you can antagonize the final fibrotic hormone with an aldosterone antagonist like epilarenome.

And your choice depends entirely on the unique patient sitting in front of you.

You tailor the therapy to protect their heart and their kidneys,

while diligently, and I mean diligently monitoring their potassium levels, their renal function, and their pregnancy status.

It really is an incredible piece of biological machinery, which brings us back to that provocative thought we opened with.

Yeah, think about the evolutionary mismatch.

We evolved this robust, redundant, multi -layered physiological system designed to fiercely retain every single milligram of sodium and tightly clamp down on our blood vessels just to survive trauma and dehydration in the ancestral environment.

And now we take that exact same ancient sodium hoarding system and we bombard it with modern fast food, sedentary lifestyles, and chronic stress.

We are essentially pouring rocket fuel into an engine that was built for a horse and buggy.

Exactly.

It raises a profound question about modern medicine.

Yeah.

Are we truly treating diseases or are we just using pharmacology to mitigate the collision between our ancient biology and our modern environment?

That is definitely something to mull over the next time you are staring at a high sodium nutrition label.

Thank you for starting with us today.

Keep up the great work.

And on behalf of the last minute lecture team here at The Deep Dive, you've got this.